Skip to main content

27.04.2024 | Blood Management (KA Tanaka, Section Editor)

Direct Oral Anticoagulants: An Update on Monitoring and Antidotes for the Perioperative Physician

verfasst von: Antasia Giebler, Roman Sniecinski

Erschienen in: Current Anesthesiology Reports

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

The purpose of this review is to update the clinician on assessing and reversing the effects of direct oral anticoagulants (DOACs) in the perioperative period.

Recent Findings

Traditional coagulation tests such as the PT and aPTT are not recommended to determine clinically significant effects of DOACs. Instead, the dilute thrombin time and chromogenic anti-Xa level can be used to guide the need for reversal of direct thrombin inhibitors and Factor Xa inhibitors respectively. Additionally, point of care assays such as viscoelastic testing and urine screening are under investigation. Current reversal strategies include the use of idarucizumab, andexanet alfa, and prothrombin complex concentrates prior to emergent surgery that cannot be delayed for DOAC effects to dissipate.

Summary

Given their relatively short half-lives, regular monitoring of DOACs is not needed, but perioperative physicians should be aware of available tests for determining the need to emergently reverse their effects.
Literatur
1.
Zurück zum Zitat • Mehta RS. Novel oral anticoagulants for prophylaxis and treatment of venous thromboembolism: part I (Factor Xa inhibitors). Expert Rev Hematol. 2010;3(2):227–41. Excellent review on the development and pharmacology of Factor Xa Inhibitors. • Mehta RS. Novel oral anticoagulants for prophylaxis and treatment of venous thromboembolism: part I (Factor Xa inhibitors). Expert Rev Hematol. 2010;3(2):227–41. Excellent review on the development and pharmacology of Factor Xa Inhibitors.
2.
3.
Zurück zum Zitat Iyer GS, Tesfaye H, Khan NF, Zakoul H, Bykov K. Trends in the Use of Oral Anticoagulants for Adults With Venous Thromboembolism in the US, 2010–2020. JAMA Netw Open. 2023;6(3): e234059.PubMedPubMedCentralCrossRef Iyer GS, Tesfaye H, Khan NF, Zakoul H, Bykov K. Trends in the Use of Oral Anticoagulants for Adults With Venous Thromboembolism in the US, 2010–2020. JAMA Netw Open. 2023;6(3): e234059.PubMedPubMedCentralCrossRef
4.
Zurück zum Zitat Colacci M, Tseng EK, Sacks CA, Fralick M. Oral Anticoagulant Utilization in the United States and United Kingdom. J Gen Intern Med. 2020;35(8):2505–7.PubMedPubMedCentralCrossRef Colacci M, Tseng EK, Sacks CA, Fralick M. Oral Anticoagulant Utilization in the United States and United Kingdom. J Gen Intern Med. 2020;35(8):2505–7.PubMedPubMedCentralCrossRef
5.
6.
Zurück zum Zitat Koster A, Faraoni D, Levy JH. Argatroban and Bivalirudin for Perioperative Anticoagulation in Cardiac Surgery. Anesthesiology. 2018;128(2):390–400.PubMedCrossRef Koster A, Faraoni D, Levy JH. Argatroban and Bivalirudin for Perioperative Anticoagulation in Cardiac Surgery. Anesthesiology. 2018;128(2):390–400.PubMedCrossRef
7.
Zurück zum Zitat Stangier J. Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate. Clin Pharmacokinet. 2008;47(5):285–95.PubMedCrossRef Stangier J. Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate. Clin Pharmacokinet. 2008;47(5):285–95.PubMedCrossRef
8.
Zurück zum Zitat Ganetsky M, Babu KM, Salhanick SD, Brown RS, Boyer EW. Dabigatran: review of pharmacology and management of bleeding complications of this novel oral anticoagulant. J Med Toxicol. 2011;7(4):281–7.PubMedPubMedCentralCrossRef Ganetsky M, Babu KM, Salhanick SD, Brown RS, Boyer EW. Dabigatran: review of pharmacology and management of bleeding complications of this novel oral anticoagulant. J Med Toxicol. 2011;7(4):281–7.PubMedPubMedCentralCrossRef
9.
Zurück zum Zitat Ripoll JG, Klompas AM, Smith BB, Smith MM. Contemporary Perioperative Management of Direct Oral Anticoagulants. Adv Anesth. 2022;40(1):93–109.PubMedCrossRef Ripoll JG, Klompas AM, Smith BB, Smith MM. Contemporary Perioperative Management of Direct Oral Anticoagulants. Adv Anesth. 2022;40(1):93–109.PubMedCrossRef
11.
Zurück zum Zitat Mann KG, Brummel K, Butenas S. What is all that thrombin for? J Thromb Haemost. 2003;1(7):1504–14.PubMedCrossRef Mann KG, Brummel K, Butenas S. What is all that thrombin for? J Thromb Haemost. 2003;1(7):1504–14.PubMedCrossRef
12.
Zurück zum Zitat Turpie AG. Oral, direct factor Xa inhibitors in development for the prevention and treatment of thromboembolic diseases. Arterioscler Thromb Vasc Biol. 2007;27(6):1238–47.PubMedCrossRef Turpie AG. Oral, direct factor Xa inhibitors in development for the prevention and treatment of thromboembolic diseases. Arterioscler Thromb Vasc Biol. 2007;27(6):1238–47.PubMedCrossRef
13.
Zurück zum Zitat Pham C, Le K, Draves M, Seoane-Vazquez E. Assessment of FDA-Approved Drugs Not Recommended for Use or Reimbursement in Other Countries, 2017–2020. JAMA Intern Med. 2023;183(4):290–7.PubMedPubMedCentralCrossRef Pham C, Le K, Draves M, Seoane-Vazquez E. Assessment of FDA-Approved Drugs Not Recommended for Use or Reimbursement in Other Countries, 2017–2020. JAMA Intern Med. 2023;183(4):290–7.PubMedPubMedCentralCrossRef
14.
Zurück zum Zitat •• Moster M, Bolliger D. Perioperative Guidelines on Antiplatelet and Anticoagulant Agents: 2022 Update. Curr Anesthesiol Rep. 2022;12(2):286–96. Review providing an update on the guidelines for perioperative management of anticoagulants and antiplatelet agents.. •• Moster M, Bolliger D. Perioperative Guidelines on Antiplatelet and Anticoagulant Agents: 2022 Update. Curr Anesthesiol Rep. 2022;12(2):286–96. Review providing an update on the guidelines for perioperative management of anticoagulants and antiplatelet agents..
15.
Zurück zum Zitat Byon W, Garonzik S, Boyd RA, Frost CE. Apixaban: A Clinical Pharmacokinetic and Pharmacodynamic Review. Clin Pharmacokinet. 2019;58(10):1265–79.PubMedPubMedCentralCrossRef Byon W, Garonzik S, Boyd RA, Frost CE. Apixaban: A Clinical Pharmacokinetic and Pharmacodynamic Review. Clin Pharmacokinet. 2019;58(10):1265–79.PubMedPubMedCentralCrossRef
16.
Zurück zum Zitat Mueck W, Stampfuss J, Kubitza D, Becka M. Clinical pharmacokinetic and pharmacodynamic profile of rivaroxaban. Clin Pharmacokinet. 2014;53(1):1–16.PubMedCrossRef Mueck W, Stampfuss J, Kubitza D, Becka M. Clinical pharmacokinetic and pharmacodynamic profile of rivaroxaban. Clin Pharmacokinet. 2014;53(1):1–16.PubMedCrossRef
17.
Zurück zum Zitat Parasrampuria DA, Truitt KE. Pharmacokinetics and Pharmacodynamics of Edoxaban, a Non-Vitamin K Antagonist Oral Anticoagulant that Inhibits Clotting Factor Xa. Clin Pharmacokinet. 2016;55(6):641–55.PubMedCrossRef Parasrampuria DA, Truitt KE. Pharmacokinetics and Pharmacodynamics of Edoxaban, a Non-Vitamin K Antagonist Oral Anticoagulant that Inhibits Clotting Factor Xa. Clin Pharmacokinet. 2016;55(6):641–55.PubMedCrossRef
18.
Zurück zum Zitat Bang HI, Lee JY, Kim HY, Shin S, Nam MH, Kim IS, et al. Coagulation Testing in Real-World Setting: Insights From a Comprehensive Survey. Clin Appl Thromb Hemost. 2024;30:10760296241228240.PubMedPubMedCentralCrossRef Bang HI, Lee JY, Kim HY, Shin S, Nam MH, Kim IS, et al. Coagulation Testing in Real-World Setting: Insights From a Comprehensive Survey. Clin Appl Thromb Hemost. 2024;30:10760296241228240.PubMedPubMedCentralCrossRef
19.
Zurück zum Zitat Margetic S, Goreta SS, Celap I, Razum M. Direct oral anticoagulants (DOACs): From the laboratory point of view. Acta Pharm. 2022;72(4):459–82.PubMedCrossRef Margetic S, Goreta SS, Celap I, Razum M. Direct oral anticoagulants (DOACs): From the laboratory point of view. Acta Pharm. 2022;72(4):459–82.PubMedCrossRef
20.
Zurück zum Zitat Tomaselli GF, Mahaffey KW, Cuker A, Dobesh PP, Doherty JU, Eikelboom JW, et al. 2017 ACC Expert Consensus Decision Pathway on Management of Bleeding in Patients on Oral Anticoagulants. J Am Coll Cardiol. 2017;70(24):3042–67.PubMedCrossRef Tomaselli GF, Mahaffey KW, Cuker A, Dobesh PP, Doherty JU, Eikelboom JW, et al. 2017 ACC Expert Consensus Decision Pathway on Management of Bleeding in Patients on Oral Anticoagulants. J Am Coll Cardiol. 2017;70(24):3042–67.PubMedCrossRef
21.
Zurück zum Zitat Netley J, Roy J, Greenlee J, Hart S, Todt M, Statz B. Bivalirudin Anticoagulation Dosing Protocol for Extracorporeal Membrane Oxygenation: A Retrospective Review. J Extra Corpor Technol. 2018;50(3):161–6.PubMedPubMedCentralCrossRef Netley J, Roy J, Greenlee J, Hart S, Todt M, Statz B. Bivalirudin Anticoagulation Dosing Protocol for Extracorporeal Membrane Oxygenation: A Retrospective Review. J Extra Corpor Technol. 2018;50(3):161–6.PubMedPubMedCentralCrossRef
22.
Zurück zum Zitat Beiderlinden M, Treschan T, Gorlinger K, Peters J. Argatroban in extracorporeal membrane oxygenation. Artif Organs. 2007;31(6):461–5.PubMedCrossRef Beiderlinden M, Treschan T, Gorlinger K, Peters J. Argatroban in extracorporeal membrane oxygenation. Artif Organs. 2007;31(6):461–5.PubMedCrossRef
23.
Zurück zum Zitat Beyer JT, Lind SE, Fisher S, Trujillo TC, Wempe MF, Kiser TH. Evaluation of intravenous direct thrombin inhibitor monitoring tests: Correlation with plasma concentrations and clinical outcomes in hospitalized patients. J Thromb Thrombolysis. 2020;49(2):259–67.PubMedCrossRef Beyer JT, Lind SE, Fisher S, Trujillo TC, Wempe MF, Kiser TH. Evaluation of intravenous direct thrombin inhibitor monitoring tests: Correlation with plasma concentrations and clinical outcomes in hospitalized patients. J Thromb Thrombolysis. 2020;49(2):259–67.PubMedCrossRef
24.
Zurück zum Zitat Gosselin RC, Adcock DM, Bates SM, Douxfils J, Favaloro EJ, Gouin-Thibault I, et al. International Council for Standardization in Haematology (ICSH) Recommendations for Laboratory Measurement of Direct Oral Anticoagulants. Thromb Haemost. 2018;118(3):437–50.PubMedCrossRef Gosselin RC, Adcock DM, Bates SM, Douxfils J, Favaloro EJ, Gouin-Thibault I, et al. International Council for Standardization in Haematology (ICSH) Recommendations for Laboratory Measurement of Direct Oral Anticoagulants. Thromb Haemost. 2018;118(3):437–50.PubMedCrossRef
25.
Zurück zum Zitat Dube C, Douketis JD, Moffat KA, Schulman S, Blais N. Basic coagulation tests as surrogates of dabigatran levels in a pre-operative setting: Analysis of five activated partial thromboplastin time reagents and thrombin time. Thromb Res. 2018;171:62–7.PubMedCrossRef Dube C, Douketis JD, Moffat KA, Schulman S, Blais N. Basic coagulation tests as surrogates of dabigatran levels in a pre-operative setting: Analysis of five activated partial thromboplastin time reagents and thrombin time. Thromb Res. 2018;171:62–7.PubMedCrossRef
26.
Zurück zum Zitat Testa S, Legnani C, Tripodi A, Paoletti O, Pengo V, Abbate R, et al. Poor comparability of coagulation screening test with specific measurement in patients receiving direct oral anticoagulants: results from a multicenter/multiplatform study. J Thromb Haemost. 2016;14(11):2194–201.PubMedCrossRef Testa S, Legnani C, Tripodi A, Paoletti O, Pengo V, Abbate R, et al. Poor comparability of coagulation screening test with specific measurement in patients receiving direct oral anticoagulants: results from a multicenter/multiplatform study. J Thromb Haemost. 2016;14(11):2194–201.PubMedCrossRef
27.
Zurück zum Zitat Jabet A, Stepanian A, Golmard JL, Flaujac C, Joly BS, Gouin-Thibault I, et al. Are Screening Tests Reliable to Rule Out Direct Oral Anticoagulant Plasma Levels at Various Thresholds (30, 50, or 100 ng/mL) in Emergency Situations? Chest. 2018;153(1):288–90.PubMedCrossRef Jabet A, Stepanian A, Golmard JL, Flaujac C, Joly BS, Gouin-Thibault I, et al. Are Screening Tests Reliable to Rule Out Direct Oral Anticoagulant Plasma Levels at Various Thresholds (30, 50, or 100 ng/mL) in Emergency Situations? Chest. 2018;153(1):288–90.PubMedCrossRef
28.
Zurück zum Zitat Francart SJ, Hawes EM, Deal AM, Adcock DM, Gosselin R, Jeanneret C, et al. Performance of coagulation tests in patients on therapeutic doses of rivaroxaban. A cross-sectional pharmacodynamic study based on peak and trough plasma levels. Thromb Haemost. 2014;111(6):1133–40.PubMedCrossRef Francart SJ, Hawes EM, Deal AM, Adcock DM, Gosselin R, Jeanneret C, et al. Performance of coagulation tests in patients on therapeutic doses of rivaroxaban. A cross-sectional pharmacodynamic study based on peak and trough plasma levels. Thromb Haemost. 2014;111(6):1133–40.PubMedCrossRef
29.
Zurück zum Zitat Dale BJ, Chan NC, Eikelboom JW. Laboratory measurement of the direct oral anticoagulants. Br J Haematol. 2016;172(3):315–36.PubMedCrossRef Dale BJ, Chan NC, Eikelboom JW. Laboratory measurement of the direct oral anticoagulants. Br J Haematol. 2016;172(3):315–36.PubMedCrossRef
30.
31.
Zurück zum Zitat Hawes EM, Deal AM, Funk-Adcock D, Gosselin R, Jeanneret C, Cook AM, et al. Performance of coagulation tests in patients on therapeutic doses of dabigatran: a cross-sectional pharmacodynamic study based on peak and trough plasma levels. J Thromb Haemost. 2013;11(8):1493–502.PubMedCrossRef Hawes EM, Deal AM, Funk-Adcock D, Gosselin R, Jeanneret C, Cook AM, et al. Performance of coagulation tests in patients on therapeutic doses of dabigatran: a cross-sectional pharmacodynamic study based on peak and trough plasma levels. J Thromb Haemost. 2013;11(8):1493–502.PubMedCrossRef
32.
Zurück zum Zitat Dean CL. An Overview of Heparin Monitoring with the Anti-Xa Assay. In: Favaloro EJ, Gosselin RC, editors. Hemostasis and Thrombosis: Methods and Protocols 343-53. New York, NY: Springer, US; 2023. Dean CL. An Overview of Heparin Monitoring with the Anti-Xa Assay. In: Favaloro EJ, Gosselin RC, editors. Hemostasis and Thrombosis: Methods and Protocols 343-53. New York, NY: Springer, US; 2023.
33.
Zurück zum Zitat Barrett YC, Wang Z, Frost C, Shenker A. Clinical laboratory measurement of direct factor Xa inhibitors: anti-Xa assay is preferable to prothrombin time assay. Thromb Haemost. 2010;104(6):1263–71.PubMed Barrett YC, Wang Z, Frost C, Shenker A. Clinical laboratory measurement of direct factor Xa inhibitors: anti-Xa assay is preferable to prothrombin time assay. Thromb Haemost. 2010;104(6):1263–71.PubMed
34.
Zurück zum Zitat Harenberg J, Erdle S, Marx S, Kramer R. Determination of rivaroxaban in human plasma samples. Semin Thromb Hemost. 2012;38(2):178–84.PubMedCrossRef Harenberg J, Erdle S, Marx S, Kramer R. Determination of rivaroxaban in human plasma samples. Semin Thromb Hemost. 2012;38(2):178–84.PubMedCrossRef
35.
Zurück zum Zitat Beyer J, Trujillo T, Fisher S, Ko A, Lind SE, Kiser TH. Evaluation of a Heparin-Calibrated Antifactor Xa Assay for Measuring the Anticoagulant Effect of Oral Direct Xa Inhibitors. Clin Appl Thromb Hemost. 2016;22(5):423–8.PubMedCrossRef Beyer J, Trujillo T, Fisher S, Ko A, Lind SE, Kiser TH. Evaluation of a Heparin-Calibrated Antifactor Xa Assay for Measuring the Anticoagulant Effect of Oral Direct Xa Inhibitors. Clin Appl Thromb Hemost. 2016;22(5):423–8.PubMedCrossRef
36.
Zurück zum Zitat • Maier CL, Asbury WH, Duncan A, Robbins A, Ingle A, Webb A, et al. Using an old test for new tricks: Measuring direct oral anti-Xa drug levels by conventional heparin-calibrated anti-Xa assay. Am J Hematol. 2019;94(5):E132–4. Brief paper explaining how to construct correlation curves for Factor Xa inhibitors using standard chromogenic Xa reagents for heparin.PubMedPubMedCentralCrossRef • Maier CL, Asbury WH, Duncan A, Robbins A, Ingle A, Webb A, et al. Using an old test for new tricks: Measuring direct oral anti-Xa drug levels by conventional heparin-calibrated anti-Xa assay. Am J Hematol. 2019;94(5):E132–4. Brief paper explaining how to construct correlation curves for Factor Xa inhibitors using standard chromogenic Xa reagents for heparin.PubMedPubMedCentralCrossRef
37.
Zurück zum Zitat Riahi N, Rozen L, Demulder A. Usefullness of Heparin Calibrated Anti-Xa Activity to Assess Anticoagulant Activity of Apixaban and Rivaroxaban in Emergency Patients Scheduled for Acute Interventions. J Clin Med. 2023;12(21). https://doi.org/10.3390/jcm12216785. Riahi N, Rozen L, Demulder A. Usefullness of Heparin Calibrated Anti-Xa Activity to Assess Anticoagulant Activity of Apixaban and Rivaroxaban in Emergency Patients Scheduled for Acute Interventions. J Clin Med. 2023;12(21). https://​doi.​org/​10.​3390/​jcm12216785.
38.
Zurück zum Zitat Gosselin RC, Dwyre DM, Dager WE. Measuring dabigatran concentrations using a chromogenic ecarin clotting time assay. Ann Pharmacother. 2013;47(12):1635–40.PubMedCrossRef Gosselin RC, Dwyre DM, Dager WE. Measuring dabigatran concentrations using a chromogenic ecarin clotting time assay. Ann Pharmacother. 2013;47(12):1635–40.PubMedCrossRef
39.
Zurück zum Zitat • de Fautereau-Vassel A, Mokhtarian A, Mangenot M, Krekounian O, Kousignian I, Delavenne X, et al. Comparisons between diluted thrombin time, ecarin chromogenic assays, and UPLC-MS for plasma level dabigatran quantification: Results from DRIVING study. Int J Lab Hematol. 2024;46(1):120–7. Large study verifying agreement of diluted thrombin time abd ecarin chromogenic assay with dabigatran levels.PubMedCrossRef • de Fautereau-Vassel A, Mokhtarian A, Mangenot M, Krekounian O, Kousignian I, Delavenne X, et al. Comparisons between diluted thrombin time, ecarin chromogenic assays, and UPLC-MS for plasma level dabigatran quantification: Results from DRIVING study. Int J Lab Hematol. 2024;46(1):120–7. Large study verifying agreement of diluted thrombin time abd ecarin chromogenic assay with dabigatran levels.PubMedCrossRef
40.
Zurück zum Zitat McGrail R, Revsholm J, Nissen PH, Grove EL, Hvas AM. Stability of direct oral anticoagulants in whole blood and plasma from patients in steady state treatment. Thromb Res. 2016;148:107–10.PubMedCrossRef McGrail R, Revsholm J, Nissen PH, Grove EL, Hvas AM. Stability of direct oral anticoagulants in whole blood and plasma from patients in steady state treatment. Thromb Res. 2016;148:107–10.PubMedCrossRef
41.
Zurück zum Zitat •• Sahli SD, Castellucci C, Roche TR, Rössler J, Spahn DR, Kaserer A. The impact of direct oral anticoagulants on viscoelastic testing - A systematic review. Front Cardiovasc Med. 2022;9: 991675. Review of the literature to date on using viscoelastic testing for DOAC assessment.PubMedPubMedCentralCrossRef •• Sahli SD, Castellucci C, Roche TR, Rössler J, Spahn DR, Kaserer A. The impact of direct oral anticoagulants on viscoelastic testing - A systematic review. Front Cardiovasc Med. 2022;9: 991675. Review of the literature to date on using viscoelastic testing for DOAC assessment.PubMedPubMedCentralCrossRef
42.
Zurück zum Zitat Vedovati MC, Mosconi MG, Isidori F, Agnelli G, Becattini C. Global thromboelastometry in patients receiving direct oral anticoagulants: the RO-DOA study. J Thromb Thrombolysis. 2020;49(2):251–8.PubMedCrossRef Vedovati MC, Mosconi MG, Isidori F, Agnelli G, Becattini C. Global thromboelastometry in patients receiving direct oral anticoagulants: the RO-DOA study. J Thromb Thrombolysis. 2020;49(2):251–8.PubMedCrossRef
43.
Zurück zum Zitat Oberladstatter D, Voelckel W, Schlimp C, Zipperle J, Ziegler B, Grottke O, et al. A prospective observational study of the rapid detection of clinically-relevant plasma direct oral anticoagulant levels following acute traumatic injury. Anaesthesia. 2021;76(3):373–80.PubMedCrossRef Oberladstatter D, Voelckel W, Schlimp C, Zipperle J, Ziegler B, Grottke O, et al. A prospective observational study of the rapid detection of clinically-relevant plasma direct oral anticoagulant levels following acute traumatic injury. Anaesthesia. 2021;76(3):373–80.PubMedCrossRef
44.
Zurück zum Zitat Bliden KP, Chaudhary R, Mohammed N, Muresan AA, Lopez-Espina CG, Cohen E, et al. Determination of non-Vitamin K oral anticoagulant (NOAC) effects using a new-generation thrombelastography TEG 6s system. J Thromb Thrombolysis. 2017;43(4):437–45.PubMedCrossRef Bliden KP, Chaudhary R, Mohammed N, Muresan AA, Lopez-Espina CG, Cohen E, et al. Determination of non-Vitamin K oral anticoagulant (NOAC) effects using a new-generation thrombelastography TEG 6s system. J Thromb Thrombolysis. 2017;43(4):437–45.PubMedCrossRef
45.
Zurück zum Zitat Artang R, Dias JD, Walsh M, Bliden K, Nielsen JD, Anderson M, et al. Measurement of Anticoagulation in Patients on Dabigatran, Rivaroxaban, and Apixaban Therapy by Novel Automated Thrombelastography. TH Open. 2021;5(4):e570–6.PubMedPubMedCentralCrossRef Artang R, Dias JD, Walsh M, Bliden K, Nielsen JD, Anderson M, et al. Measurement of Anticoagulation in Patients on Dabigatran, Rivaroxaban, and Apixaban Therapy by Novel Automated Thrombelastography. TH Open. 2021;5(4):e570–6.PubMedPubMedCentralCrossRef
46.
Zurück zum Zitat •• Douxfils J, Adcock DM, Bates SM, Favaloro EJ, Gouin-Thibault I, Guillermo C, et al. 2021 Update of the International Council for Standardization in Haematology Recommendations for Laboratory Measurement of Direct Oral Anticoagulants. Thromb Haemost. 2021;121(8):1008–20. Expert concensus on measuring DOAC levels.PubMedCrossRef •• Douxfils J, Adcock DM, Bates SM, Favaloro EJ, Gouin-Thibault I, Guillermo C, et al. 2021 Update of the International Council for Standardization in Haematology Recommendations for Laboratory Measurement of Direct Oral Anticoagulants. Thromb Haemost. 2021;121(8):1008–20. Expert concensus on measuring DOAC levels.PubMedCrossRef
47.
Zurück zum Zitat Harenberg J, Schreiner R, Hetjens S, Weiss C. Detecting Anti-IIa and Anti-Xa Direct Oral Anticoagulant (DOAC) Agents in Urine using a DOAC Dipstick. Semin Thromb Hemost. 2019;45(3):275–84.PubMedCrossRef Harenberg J, Schreiner R, Hetjens S, Weiss C. Detecting Anti-IIa and Anti-Xa Direct Oral Anticoagulant (DOAC) Agents in Urine using a DOAC Dipstick. Semin Thromb Hemost. 2019;45(3):275–84.PubMedCrossRef
48.
Zurück zum Zitat Harenberg J, Gosselin RC, Cuker A, Becattini C, Pabinger I, Poli S, et al. Algorithm for rapid exclusion of clinically relevant plasma levels of DOACs in patients using the DOAC Dipstick. An expert consensus paper. Thromb Haemost. 2024. https://doi.org/10.1055/a-2261-1811. Harenberg J, Gosselin RC, Cuker A, Becattini C, Pabinger I, Poli S, et al. Algorithm for rapid exclusion of clinically relevant plasma levels of DOACs in patients using the DOAC Dipstick. An expert consensus paper. Thromb Haemost. 2024. https://​doi.​org/​10.​1055/​a-2261-1811.
49.
Zurück zum Zitat •• Levy JH, Ageno W, Chan NC, Crowther M, Verhamme P, Weitz JI, et al. When and how to use antidotes for the reversal of direct oral anticoagulants: guidance from the SSC of the ISTH. J Thromb Haemost. 2016;14(3):623–7. Expert consensus on when to reverse DOAC anticoagulation effects.PubMedCrossRef •• Levy JH, Ageno W, Chan NC, Crowther M, Verhamme P, Weitz JI, et al. When and how to use antidotes for the reversal of direct oral anticoagulants: guidance from the SSC of the ISTH. J Thromb Haemost. 2016;14(3):623–7. Expert consensus on when to reverse DOAC anticoagulation effects.PubMedCrossRef
50.
Zurück zum Zitat Eikelboom JW, van Ryn J, Reilly P, Hylek EM, Elsaesser A, Glund S, et al. Dabigatran Reversal With Idarucizumab in Patients With Renal Impairment. J Am Coll Cardiol. 2019;74(14):1760–8.PubMedCrossRef Eikelboom JW, van Ryn J, Reilly P, Hylek EM, Elsaesser A, Glund S, et al. Dabigatran Reversal With Idarucizumab in Patients With Renal Impairment. J Am Coll Cardiol. 2019;74(14):1760–8.PubMedCrossRef
51.
Zurück zum Zitat Schmohl M, Glund S, Harada A, Imazu S, De Smet M, Moschetti V, et al. Idarucizumab does not have procoagulant effects: Assessment of thrombosis biomarkers in healthy volunteers. Thromb Haemost. 2017;117(2):269–76.PubMedCrossRef Schmohl M, Glund S, Harada A, Imazu S, De Smet M, Moschetti V, et al. Idarucizumab does not have procoagulant effects: Assessment of thrombosis biomarkers in healthy volunteers. Thromb Haemost. 2017;117(2):269–76.PubMedCrossRef
52.
Zurück zum Zitat Pollack CV Jr, Reilly PA, van Ryn J, Eikelboom JW, Glund S, Bernstein RA, et al. Idarucizumab for Dabigatran Reversal - Full Cohort Analysis. N Engl J Med. 2017;377(5):431–41.PubMedCrossRef Pollack CV Jr, Reilly PA, van Ryn J, Eikelboom JW, Glund S, Bernstein RA, et al. Idarucizumab for Dabigatran Reversal - Full Cohort Analysis. N Engl J Med. 2017;377(5):431–41.PubMedCrossRef
53.
Zurück zum Zitat van der Horst SFB, Martens ESL, den Exter PL, Bos MHA, van Mens TE, Huisman MV, et al. Idarucizumab for dabigatran reversal: A systematic review and meta-analysis of indications and outcomes. Thromb Res. 2023;228:21–32.PubMedCrossRef van der Horst SFB, Martens ESL, den Exter PL, Bos MHA, van Mens TE, Huisman MV, et al. Idarucizumab for dabigatran reversal: A systematic review and meta-analysis of indications and outcomes. Thromb Res. 2023;228:21–32.PubMedCrossRef
54.
Zurück zum Zitat Writing Committee M, Joglar JA, Chung MK, Armbruster AL, Benjamin EJ, Chyou JY, et al. 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2024;83(1):109–279.CrossRef Writing Committee M, Joglar JA, Chung MK, Armbruster AL, Benjamin EJ, Chyou JY, et al. 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2024;83(1):109–279.CrossRef
55.
Zurück zum Zitat Levy JH, Douketis J, Weitz JI. Reversal agents for non-vitamin K antagonist oral anticoagulants. Nat Rev Cardiol. 2018;15(5):273–81.PubMedCrossRef Levy JH, Douketis J, Weitz JI. Reversal agents for non-vitamin K antagonist oral anticoagulants. Nat Rev Cardiol. 2018;15(5):273–81.PubMedCrossRef
56.
Zurück zum Zitat Siegal DM, Curnutte JT, Connolly SJ, Lu G, Conley PB, Wiens BL, et al. Andexanet Alfa for the Reversal of Factor Xa Inhibitor Activity. N Engl J Med. 2015;373(25):2413–24.PubMedCrossRef Siegal DM, Curnutte JT, Connolly SJ, Lu G, Conley PB, Wiens BL, et al. Andexanet Alfa for the Reversal of Factor Xa Inhibitor Activity. N Engl J Med. 2015;373(25):2413–24.PubMedCrossRef
57.
Zurück zum Zitat Brenner B, Guerra J, Williams C, Littlewood K, Kern J, Tanaka K, et al. Heparin Insensitivity and Thrombotic Risk Associated With Sequential Uses of Prothrombin Complex Concentrate and Andexanet Alfa for Apixaban Reversal During Acute Type A Aortic Dissection Repair: A Case Report. A A Pract. 2022;16(11): e01636.PubMedPubMedCentralCrossRef Brenner B, Guerra J, Williams C, Littlewood K, Kern J, Tanaka K, et al. Heparin Insensitivity and Thrombotic Risk Associated With Sequential Uses of Prothrombin Complex Concentrate and Andexanet Alfa for Apixaban Reversal During Acute Type A Aortic Dissection Repair: A Case Report. A A Pract. 2022;16(11): e01636.PubMedPubMedCentralCrossRef
58.
Zurück zum Zitat Nozumi Y, Yonezawa Y, Yunoki K, Mima H. Cardiopulmonary Bypass Circuit Obstruction and Urgent Replacement After the Administration of Andexanet Alfa. J Cardiothorac Vasc Anesth. 2024;38(3):780–3.PubMedCrossRef Nozumi Y, Yonezawa Y, Yunoki K, Mima H. Cardiopulmonary Bypass Circuit Obstruction and Urgent Replacement After the Administration of Andexanet Alfa. J Cardiothorac Vasc Anesth. 2024;38(3):780–3.PubMedCrossRef
59.
Zurück zum Zitat Milling TJ Jr, Middeldorp S, Xu L, Koch B, Demchuk A, Eikelboom JW, et al. Final Study Report of Andexanet Alfa for Major Bleeding With Factor Xa Inhibitors. Circulation. 2023;147(13):1026–38.PubMedCrossRef Milling TJ Jr, Middeldorp S, Xu L, Koch B, Demchuk A, Eikelboom JW, et al. Final Study Report of Andexanet Alfa for Major Bleeding With Factor Xa Inhibitors. Circulation. 2023;147(13):1026–38.PubMedCrossRef
61.
Zurück zum Zitat Spyropoulos AC, Hartaigh BO, Cao Z, Caberwal H, Lipkin C, Petrini M, et al. Costs and Healthcare Resource Utilization Associated with Idarucizumab or Andexanet Alfa Oral Anticoagulant Reversal in Patients Hospitalized with Life-Threatening Bleeds. Clin Appl Thromb Hemost. 2022;28:10760296221110568.PubMedPubMedCentralCrossRef Spyropoulos AC, Hartaigh BO, Cao Z, Caberwal H, Lipkin C, Petrini M, et al. Costs and Healthcare Resource Utilization Associated with Idarucizumab or Andexanet Alfa Oral Anticoagulant Reversal in Patients Hospitalized with Life-Threatening Bleeds. Clin Appl Thromb Hemost. 2022;28:10760296221110568.PubMedPubMedCentralCrossRef
62.
Zurück zum Zitat Deng H, Nutescu EA, DiDomenico RJ. Reversal of Oral Anticoagulants: A Survey of Contemporary Practice Trends (ReACT). Clin Appl Thromb Hemost. 2023;29:10760296231176808.PubMedPubMedCentralCrossRef Deng H, Nutescu EA, DiDomenico RJ. Reversal of Oral Anticoagulants: A Survey of Contemporary Practice Trends (ReACT). Clin Appl Thromb Hemost. 2023;29:10760296231176808.PubMedPubMedCentralCrossRef
63.
Zurück zum Zitat Levy JH, Douketis J, Steiner T, Goldstein JN, Milling TJ. Prothrombin Complex Concentrates for Perioperative Vitamin K Antagonist and Non-vitamin K Anticoagulant Reversal. Anesthesiology. 2018;129(6):1171–84.PubMedCrossRef Levy JH, Douketis J, Steiner T, Goldstein JN, Milling TJ. Prothrombin Complex Concentrates for Perioperative Vitamin K Antagonist and Non-vitamin K Anticoagulant Reversal. Anesthesiology. 2018;129(6):1171–84.PubMedCrossRef
64.
Zurück zum Zitat • Tanaka KA, Shettar S, Vandyck K, Shea SM, Abuelkasem E. Roles of Four-Factor Prothrombin Complex Concentrate in the Management of Critical Bleeding. Transfus Med Rev. 2021;35(4):96–103. Excellent review of 4-factor PCC use in psot-CPB coagulopathy, major trauma, liver failure, and Factor Xa inhibitor reversal.PubMedCrossRef • Tanaka KA, Shettar S, Vandyck K, Shea SM, Abuelkasem E. Roles of Four-Factor Prothrombin Complex Concentrate in the Management of Critical Bleeding. Transfus Med Rev. 2021;35(4):96–103. Excellent review of 4-factor PCC use in psot-CPB coagulopathy, major trauma, liver failure, and Factor Xa inhibitor reversal.PubMedCrossRef
65.
Zurück zum Zitat Makris M, Watson HG. The management of coumarin-induced over-anticoagulation Annotation. Br J Haematol. 2001;114(2):271–80.PubMedCrossRef Makris M, Watson HG. The management of coumarin-induced over-anticoagulation Annotation. Br J Haematol. 2001;114(2):271–80.PubMedCrossRef
66.
Zurück zum Zitat Sorensen B, Spahn DR, Innerhofer P, Spannagl M, Rossaint R. Clinical review: Prothrombin complex concentrates–evaluation of safety and thrombogenicity. Crit Care. 2011;15(1):201.PubMedPubMedCentralCrossRef Sorensen B, Spahn DR, Innerhofer P, Spannagl M, Rossaint R. Clinical review: Prothrombin complex concentrates–evaluation of safety and thrombogenicity. Crit Care. 2011;15(1):201.PubMedPubMedCentralCrossRef
67.
Zurück zum Zitat Panos NG, Cook AM, John S, Jones GM, Neurocritical Care Society Pharmacy Study G. Factor Xa Inhibitor-Related Intracranial Hemorrhage: Results From a Multicenter, Observational Cohort Receiving Prothrombin Complex Concentrates. Circulation. 2020;141(21):1681–9.CrossRef Panos NG, Cook AM, John S, Jones GM, Neurocritical Care Society Pharmacy Study G. Factor Xa Inhibitor-Related Intracranial Hemorrhage: Results From a Multicenter, Observational Cohort Receiving Prothrombin Complex Concentrates. Circulation. 2020;141(21):1681–9.CrossRef
68.
Zurück zum Zitat Chiasakul T, Crowther M, Cuker A. Four-factor prothrombin complex concentrate for the treatment of oral factor Xa inhibitor-associated bleeding: a meta-analysis of fixed versus variable dosing. Res Pract Thromb Haemost. 2023;7(2): 100107.PubMedPubMedCentralCrossRef Chiasakul T, Crowther M, Cuker A. Four-factor prothrombin complex concentrate for the treatment of oral factor Xa inhibitor-associated bleeding: a meta-analysis of fixed versus variable dosing. Res Pract Thromb Haemost. 2023;7(2): 100107.PubMedPubMedCentralCrossRef
69.
Zurück zum Zitat •• Cuker A, Burnett A, Triller D, Crowther M, Ansell J, Van Cott EM, et al. Reversal of direct oral anticoagulants: Guidance from the Anticoagulation Forum. Am J Hematol. 2019;94(6):697–709. Expert consensus document on revering DOAC effects.PubMedCrossRef •• Cuker A, Burnett A, Triller D, Crowther M, Ansell J, Van Cott EM, et al. Reversal of direct oral anticoagulants: Guidance from the Anticoagulation Forum. Am J Hematol. 2019;94(6):697–709. Expert consensus document on revering DOAC effects.PubMedCrossRef
Metadaten
Titel
Direct Oral Anticoagulants: An Update on Monitoring and Antidotes for the Perioperative Physician
verfasst von
Antasia Giebler
Roman Sniecinski
Publikationsdatum
27.04.2024
Verlag
Springer US
Erschienen in
Current Anesthesiology Reports
Elektronische ISSN: 2167-6275
DOI
https://doi.org/10.1007/s40140-024-00631-2

Blutdrucksenkung schon im Rettungswagen bei akutem Schlaganfall?

31.05.2024 Apoplex Nachrichten

Der optimale Ansatz für die Blutdruckkontrolle bei Patientinnen und Patienten mit akutem Schlaganfall ist noch nicht gefunden. Ob sich eine frühzeitige Therapie der Hypertonie noch während des Transports in die Klinik lohnt, hat jetzt eine Studie aus China untersucht.

Ähnliche Überlebensraten nach Reanimation während des Transports bzw. vor Ort

29.05.2024 Reanimation im Kindesalter Nachrichten

Laut einer Studie aus den USA und Kanada scheint es bei der Reanimation von Kindern außerhalb einer Klinik keinen Unterschied für das Überleben zu machen, ob die Wiederbelebungsmaßnahmen während des Transports in die Klinik stattfinden oder vor Ort ausgeführt werden. Jedoch gibt es dabei einige Einschränkungen und eine wichtige Ausnahme.

Nicht Creutzfeldt Jakob, sondern Abführtee-Vergiftung

29.05.2024 Hyponatriämie Nachrichten

Eine ältere Frau trinkt regelmäßig Sennesblättertee gegen ihre Verstopfung. Der scheint plötzlich gut zu wirken. Auf Durchfall und Erbrechen folgt allerdings eine Hyponatriämie. Nach deren Korrektur kommt es plötzlich zu progredienten Kognitions- und Verhaltensstörungen.

Häusliche Gewalt in der orthopädischen Notaufnahme oft nicht erkannt

28.05.2024 Häusliche Gewalt Nachrichten

In der Notaufnahme wird die Chance, Opfer von häuslicher Gewalt zu identifizieren, von Orthopäden und Orthopädinnen offenbar zu wenig genutzt. Darauf deuten die Ergebnisse einer Fragebogenstudie an der Sahlgrenska-Universität in Schweden hin.

Update AINS

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.